Three independent discounted-cash-flow-style models value Xenon Pharmaceuticals Inc every trading day. 0 of 3 currently price XENE above its market price.
| Free Cash Flow model | $-7.93 |
| Excess Profit model | $-3.02 |
| Residual Earnings model | $-1.27 |
| Dividend Discount model | — |
| Piotroski F-Score | 2 / 9 |
| Return on invested capital | -58.5% |
| Net debt / EBITDA | — |
| Gross margin | +100.0% |
| Revenue CAGR | -38.5% |
| Cash conversion | — |
| Dividend yield | — |
| Buyback yield | -30.9% |
These are StockKitty's default assumptions. In the app, the models recompute live as you adjust growth, discount rates, and margins — and the AI explains the bull case, bear case, and quality picture.
Open XENE in StockKitty